<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258115</url>
  </required_header>
  <id_info>
    <org_study_id>CHS 03-48</org_study_id>
    <nct_id>NCT00258115</nct_id>
  </id_info>
  <brief_title>The Study of Inflammation on Blood Glucose Levels in Obese People</brief_title>
  <official_title>The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic subaccute inflammation may underlie the development of diabetes cardiovascular
      disease and other components of the metabolic syndrome. Rodent studies suggest diet induced
      obesity is associated with activation of the IKK/NF-kB pathway and this pathway can be
      inhibited by salicylates. This study seeks to determine the effect of salicylates in
      overweight persons.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycemia</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>salsalate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4.0 g/d divided dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for salsalate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salsalate</intervention_name>
    <arm_group_label>salsalate</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obesity (&gt; 85th% for age,BMI &gt; 30); HbA1c &lt;6%; hemoglobin and/or hematocrit within 2
             standard deviations of normal range, without high risk of bleeding, without donation
             of blood in the previous 2 months; without involvement in any study evaluating an
             investigational drug or device for the previous 2 months; normal clotting studies; if
             female using barrier or oral contraception and with a negative pregnancy test.

        Exclusion Criteria:

          -  Pregnant or lactating women; Patients with abnormal liver function defined as
             elevation of bilirubin, alkaline phosphatase, ALT, AST, or GGTP more than 1.5 times
             the upper limit of normal; Patients with kidney disease (serum creatinine &gt; 1.5 mg/dL)
             macroalbuminuria (1+ protein on a standard urine dip-stick, or &gt; 300 mg urinary
             albumin/day); (patients with microalbuminuria will be enrolled); Patients with any
             significant diseases or conditions, including emotional or psychiatric disorders and
             substance abuse, including history of binge drinking, that, in the opinion of the
             investigator, are likely to alter the patient's ability to complete the study ;
             Patients with metabolic acidosis (abnormal anion gap); History of gastric ulcer,
             dyspepsia, or upper or lower GI bleed; History of allergy to aspirin, or bleeding
             diathesis or currently on oral anticoagulants including warfarin, heparin, aspirin or
             other NSAIDs; Patients with major vascular event within 6 months of screening for the
             study (e.g., MI, stroke, CABG, angioplasty, PV surgery); Patients with chronic heart
             disease, or a history of myocardial infarction or stroke. Symptomatic angina pectoris
             or cardiac insufficiency as defined by the NYHA; classification as Functional Class
             III or IV; Patients who smoke more than one pack of cigarettes daily; Patients taking
             treatment medications known to affect insulin sensitivity (e.g. diuretics,
             beta-blockers); Patients with inadequately controlled serum lipid levels (total
             cholesterol ≥ 275 mg/dL and fasting triglycerides ≥ 450 mg/dL); Patients with history
             of cancer within 5 years prior to screening for the study other than basal cell
             carcinoma; active alcohol or other substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison B. Goldfine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator/Assistant Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.joslin.org</url>
    <description>Joslin Diabetes Center Web-Site</description>
  </link>
  <reference>
    <citation>Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. Review. Erratum in: J Clin Invest. 2006 Aug;116(8):2308.</citation>
    <PMID>16823477</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.</citation>
    <PMID>19337387</PMID>
  </reference>
  <results_reference>
    <citation>Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008 Feb;31(2):289-94. Epub 2007 Oct 24.</citation>
    <PMID>17959861</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

